Cyclopharm Limited (ASX:CYC) Could Be Less Than A Year Away From Profitability

Cyclopharm Limited (ASX:CYC) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The AU$124m market-cap company announced a latest loss of AU$13m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on Cyclopharm's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Cyclopharm is bordering on breakeven, according to some Australian Medical Equipment analysts. They expect the company to post a final loss in 2024, before turning a profit of AU$600k in 2025. So, the company is predicted to breakeven approximately 12 months from now or less. How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 98% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Cyclopharm's growth isn’t the focus of this broad overview, though, bear in mind that typically a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

See our latest analysis for Cyclopharm

One thing we’d like to point out is that Cyclopharm has no debt on its balance sheet, which is quite unusual for a cash-burning growth company, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of Cyclopharm to cover in one brief article, but the key fundamentals for the company can all be found in one place – Cyclopharm's company page on Simply Wall St. We've also compiled a list of essential factors you should further examine:

1. Valuation: What is Cyclopharm worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Cyclopharm is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Cyclopharm’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.